Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B

Papatheodoridis G., Dalekos G. N., İDİLMAN R., Sypsa V., Van Boemmel F., Buti M., ...More

JOURNAL OF HEPATOLOGY, vol.73, no.5, pp.1037-1045, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 73 Issue: 5
  • Publication Date: 2020
  • Doi Number: 10.1016/j.jhep.2020.06.011
  • Journal Name: JOURNAL OF HEPATOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.1037-1045
  • Keywords: Liver cancer, Cirrhosis, Treatment, Nucleoside analogue, Nucleotide analogue, Liver stiffness, DISOPROXIL FUMARATE, HCC, SURVEILLANCE, VALIDATION, GUIDELINES
  • Ankara University Affiliated: Yes

Abstract

Background & Aims: A recent study in Asian patients with chronic hepatitis B (CHB) reported that the incidence of hepatocellular carcinoma (HCC) was lower in patients treated with tenofovir disoproxil fumarate (TDF) than entecavir (ETV), but this finding remains controversial. We aimed to identify any differences in HCC incidence, or other patient outcomes, between patients receiving TDF or ETV in the well monitored, multicenter European PAGE-B cohort.